Evofem Appoints Sandra Matsumoto As Vice President Of Global Regulatory Affairs

SAN DIEGO, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Evofem, Inc. announces that Sandra Matsumoto has been named Vice President of Global Regulatory Affairs effective immediately. In this role, Dr. Matsumoto will be responsible for global regulatory strategy and lifecycle management of the Evofem product portfolio. She will report to Evofem Senior Vice President of Regulatory Affairs and Quality Assurance, Mary Jarosz.

"Sandra has extensive experience in the biotech and pharmaceutical industry," said Jarosz. "She has implemented global strategies from development to commercialization across several therapeutic areas and is a great addition to a well-established regulatory team."

Prior to joining Evofem, Dr. Matsumoto was the Senior Director of Global Regulatory Affairs for Vital Therapeutics, Inc., where she led biologics license application preparation for the treatment of severe liver disease. Before joining Vital, she held positions with increasing levels of responsibility in the areas of regulatory affairs, clinical development, and discovery research with several companies including Shire Regenerative Medicine and Illumina.

Dr. Matsumoto earned her PhD in Pharmacology and Toxicology from the University of Utah, her Master's of Science in Biology from California State University, Northridge and her Bachelor's of Science in Biology from UCLA. She also holds RAC certifications for the U.S. and E.U.

About Evofem

Evofem, Inc. is a late stage biotechnology company, headquartered in San Diego, CA, which focuses on the development and commercialization of women's reproductive health products, with a core focus on contraception.

Evofem, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem has two lead product candidates; Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.

For further information on the Company, please visit: www.evofem.com

CONTACT: Media Inquiries Ellen Thomas +1.718.490.3248 [email protected]